The International Health Facility Diversion Association estimates that at least 37,000 drug diversion incidents occur in U.S. facilities each year, and this number is likely underreported.1
A recent webinar with the U.S. Drug Enforcement Administration (DEA), hosted by Wolters Kluwer Health, highlighted some ways organizations may be evaluated and opportunities to prevent medication diversion.
Expect several components to an onsite visit from the DEA
As discussed in the webinar, an onsite visit from the DEA can take place for several reasons. These may include a regularly scheduled inspection, when theft or loss occurs, after a patient complaint, or at the request of a hospital to help discover any issues. You can expect a DEA visit to follow a standard process.
Based on information shared during the webinar, DEA investigators will traditionally meet with health system administrators and designated controlled substance handlers. As the investigation evolves, health-system staff should be prepared to proceed with a tour of the facility and controlled substance storage areas and to discuss standard operating procedures. DEA investigators may also conduct a controlled substance document request and a physical count of controlled substances on hand, including a review of the inventory process. The webinar goes into detail on what to expect and records that may need to be produced for the audit.